SCHEMBL26686466

SCHEMBL26686466

Clc1ccnc2[nH]c(Cc3ccccc3)cc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNK O75909 1/20 0.54
▸ CDK12 Q9NYV4 1/20 0.54
▸ MAPK14 Q16539 1/20 0.48
▸ KDM4C Q9H3R0 2/20 0.44
▸ KDM4A O75164 1/20 0.44
▸ KDM5A P29375 1/20 0.44
▸ KDM5B Q9UGL1 1/20 0.44
▸ ADORA1 P30542 1/20 0.44
▸ NUDT1 P36639 1/20 0.42
▸ AOC3 Q16853 1/20 0.41
▸ PARP1 P09874 1/20 0.40
▸ CCNB2 O95067 2/20 0.40
▸ CDK1 P06493 2/20 0.40
▸ CCNB1 P14635 2/20 0.40
▸ GSK3A P49840 2/20 0.40
▸ GSK3B P49841 2/20 0.40
▸ CCNB3 Q8WWL7 2/20 0.40
▸ AURKA O14965 1/20 0.40
▸ AURKB Q96GD4 1/20 0.40
▸ MET P08581 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3492132 0.87 KDR (0.50) CCNKCDK12KDM5AKDM5BNUDT1
SCHEMBL26889157 0.79 AXL (0.41) CCNKCDK12NUDT1AURKAAURKB
SCHEMBL31420473 0.78 NUDT1 (0.59) CCNKCDK12KDM4CKDM5AKDM5B
SCHEMBL21429079 0.78 NUDT1 (0.59) CCNKCDK12KDM4CKDM5AKDM5B
SCHEMBL3415919 0.78 AXL (0.44) CCNKCDK12NUDT1PARP1AURKA
SCHEMBL30571033 0.78 AXL (0.44) CCNKCDK12NUDT1PARP1AURKA
SCHEMBL21428737 0.74 KDM5A (0.42) CCNKCDK12KDM4CKDM5AKDM5B
SCHEMBL30716680 0.74 KDM5A (0.42) CCNKCDK12KDM4CKDM5AKDM5B
SCHEMBL26686642 0.74 AXL (0.41) CCNKCDK12NUDT1AURKAAURKB
SCHEMBL2113619 0.73 DRD2 (0.53) CCNKCDK12MAPK14KDM4CKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US disclosed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 — — EP disclosed
CN-119562945-A IKK inhibitors 癌症研究技术有限公司 2025-03-04 — — CN disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304576-A1 IKK INHIBITORS NFKBIA, IKBKE, IKBKB CCNK 222/4885CDK12 171/4885MAPK14 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback